An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies. An emerging class of anticancer drugs called EZH2 inhibitors may greatly ...

The number of people receiving treatment for cancer has risen dramatically in the last decade in many African countries. For ...

Colorectal cancer is one of the most common tumors among people over the age of 50. Although it is known to develop from small lesions or polyps, its exact causes are unknown — only a few risk factors ...

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma ...

Pretreatment with EZH2 inhibitor (top right) leads to higher recruitment of CAR-T cells (red) into the lymph node tumor compared with control (top left). Pretreatment with EZH2 inhibitor (bottom right ...